Identification and validation of a novel panel of Plasmodium knowlesi biomarkers of serological exposure.

BACKGROUND:Plasmodium knowlesi is the most common cause of malaria in Malaysian Borneo, with reporting limited to clinical cases presenting to health facilities and scarce data on the true extent of transmission. Serological estimations of transmission have been used with other malaria species to ga...

Full description

Bibliographic Details
Main Authors: Lou S Herman, Kimberly Fornace, Jody Phelan, Matthew J Grigg, Nicholas M Anstey, Timothy William, Robert W Moon, Michael J Blackman, Chris J Drakeley, Kevin K A Tetteh
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2018-06-01
Series:PLoS Neglected Tropical Diseases
Online Access:http://europepmc.org/articles/PMC6001954?pdf=render
id doaj-d0d437d3cd18438aaac3016b08e432fc
record_format Article
spelling doaj-d0d437d3cd18438aaac3016b08e432fc2020-11-24T20:47:02ZengPublic Library of Science (PLoS)PLoS Neglected Tropical Diseases1935-27271935-27352018-06-01126e000645710.1371/journal.pntd.0006457Identification and validation of a novel panel of Plasmodium knowlesi biomarkers of serological exposure.Lou S HermanKimberly FornaceJody PhelanMatthew J GriggNicholas M AnsteyTimothy WilliamRobert W MoonMichael J BlackmanChris J DrakeleyKevin K A TettehBACKGROUND:Plasmodium knowlesi is the most common cause of malaria in Malaysian Borneo, with reporting limited to clinical cases presenting to health facilities and scarce data on the true extent of transmission. Serological estimations of transmission have been used with other malaria species to garner information about epidemiological patterns. However, there are a distinct lack of suitable serosurveillance tools for this neglected disease. METHODOLOGY/PRINCIPAL FINDINGS:Using in silico tools, we designed and expressed four novel P. knowlesi protein products to address the distinct lack of suitable serosurveillance tools: PkSERA3 antigens 1 and 2, PkSSP2/TRAP and PkTSERA2 antigen 1. Antibody prevalence to these antigens was determined by ELISA for three time-points post-treatment from a hospital-based clinical treatment trial in Sabah, East Malaysia (n = 97 individuals; 241 total samples for all time points). Higher responses were observed for the PkSERA3 antigen 2 (67%, 65/97) across all time-points (day 0: 36.9% 34/92; day 7: 63.8% 46/72; day 28: 58.4% 45/77) with significant differences between the clinical cases and controls (n = 55, mean plus 3 SD) (day 0 p<0.0001; day 7 p<0.0001; day 28 p<0.0001). Using boosted regression trees, we developed models to classify P. knowlesi exposure (cross-validated AUC 88.9%; IQR 86.1-91.3%) and identified the most predictive antibody responses. CONCLUSIONS/SIGNIFICANCE:The PkSERA3 antigen 2 had the highest relative variable importance in all models. Further validation of these antigens is underway to determine the specificity of these tools in the context of multi-species infections at the population level.http://europepmc.org/articles/PMC6001954?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Lou S Herman
Kimberly Fornace
Jody Phelan
Matthew J Grigg
Nicholas M Anstey
Timothy William
Robert W Moon
Michael J Blackman
Chris J Drakeley
Kevin K A Tetteh
spellingShingle Lou S Herman
Kimberly Fornace
Jody Phelan
Matthew J Grigg
Nicholas M Anstey
Timothy William
Robert W Moon
Michael J Blackman
Chris J Drakeley
Kevin K A Tetteh
Identification and validation of a novel panel of Plasmodium knowlesi biomarkers of serological exposure.
PLoS Neglected Tropical Diseases
author_facet Lou S Herman
Kimberly Fornace
Jody Phelan
Matthew J Grigg
Nicholas M Anstey
Timothy William
Robert W Moon
Michael J Blackman
Chris J Drakeley
Kevin K A Tetteh
author_sort Lou S Herman
title Identification and validation of a novel panel of Plasmodium knowlesi biomarkers of serological exposure.
title_short Identification and validation of a novel panel of Plasmodium knowlesi biomarkers of serological exposure.
title_full Identification and validation of a novel panel of Plasmodium knowlesi biomarkers of serological exposure.
title_fullStr Identification and validation of a novel panel of Plasmodium knowlesi biomarkers of serological exposure.
title_full_unstemmed Identification and validation of a novel panel of Plasmodium knowlesi biomarkers of serological exposure.
title_sort identification and validation of a novel panel of plasmodium knowlesi biomarkers of serological exposure.
publisher Public Library of Science (PLoS)
series PLoS Neglected Tropical Diseases
issn 1935-2727
1935-2735
publishDate 2018-06-01
description BACKGROUND:Plasmodium knowlesi is the most common cause of malaria in Malaysian Borneo, with reporting limited to clinical cases presenting to health facilities and scarce data on the true extent of transmission. Serological estimations of transmission have been used with other malaria species to garner information about epidemiological patterns. However, there are a distinct lack of suitable serosurveillance tools for this neglected disease. METHODOLOGY/PRINCIPAL FINDINGS:Using in silico tools, we designed and expressed four novel P. knowlesi protein products to address the distinct lack of suitable serosurveillance tools: PkSERA3 antigens 1 and 2, PkSSP2/TRAP and PkTSERA2 antigen 1. Antibody prevalence to these antigens was determined by ELISA for three time-points post-treatment from a hospital-based clinical treatment trial in Sabah, East Malaysia (n = 97 individuals; 241 total samples for all time points). Higher responses were observed for the PkSERA3 antigen 2 (67%, 65/97) across all time-points (day 0: 36.9% 34/92; day 7: 63.8% 46/72; day 28: 58.4% 45/77) with significant differences between the clinical cases and controls (n = 55, mean plus 3 SD) (day 0 p<0.0001; day 7 p<0.0001; day 28 p<0.0001). Using boosted regression trees, we developed models to classify P. knowlesi exposure (cross-validated AUC 88.9%; IQR 86.1-91.3%) and identified the most predictive antibody responses. CONCLUSIONS/SIGNIFICANCE:The PkSERA3 antigen 2 had the highest relative variable importance in all models. Further validation of these antigens is underway to determine the specificity of these tools in the context of multi-species infections at the population level.
url http://europepmc.org/articles/PMC6001954?pdf=render
work_keys_str_mv AT lousherman identificationandvalidationofanovelpanelofplasmodiumknowlesibiomarkersofserologicalexposure
AT kimberlyfornace identificationandvalidationofanovelpanelofplasmodiumknowlesibiomarkersofserologicalexposure
AT jodyphelan identificationandvalidationofanovelpanelofplasmodiumknowlesibiomarkersofserologicalexposure
AT matthewjgrigg identificationandvalidationofanovelpanelofplasmodiumknowlesibiomarkersofserologicalexposure
AT nicholasmanstey identificationandvalidationofanovelpanelofplasmodiumknowlesibiomarkersofserologicalexposure
AT timothywilliam identificationandvalidationofanovelpanelofplasmodiumknowlesibiomarkersofserologicalexposure
AT robertwmoon identificationandvalidationofanovelpanelofplasmodiumknowlesibiomarkersofserologicalexposure
AT michaeljblackman identificationandvalidationofanovelpanelofplasmodiumknowlesibiomarkersofserologicalexposure
AT chrisjdrakeley identificationandvalidationofanovelpanelofplasmodiumknowlesibiomarkersofserologicalexposure
AT kevinkatetteh identificationandvalidationofanovelpanelofplasmodiumknowlesibiomarkersofserologicalexposure
_version_ 1716811444684587008